구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | KN5501 (anti-CD19 CAR NK cells, anti-CD19 CAR NK cells (KN5501)) Rui Therapeutics Co., Ltd·CD19 33 trials |
|---|---|
Overview Program | anti-CD19 CAR NK cells (KN5501) |
Overview Company | Rui Therapeutics Co., Ltd |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Systemic Lupus Erythematosus (SLE) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Constitutive RLI Armoring Enhances CAR-NK Cell Effector Functions but Causes Lethal Toxicity In Vivo.. Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is a promising immunotherapy for hematological malignancies. While engineered interleukin15 (IL15) variants like membrane-bound IL15 (mbIL15) and the IL15/IL15Rα heterodimer (RLI) can enhance NK cell activity, their relative eff… |
Toxicology CRS | Reported |
Clinical Safety signal | Constitutive RLI Armoring Enhances CAR-NK Cell Effector Functions but Causes Lethal Toxicity In Vivo.. Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is a promising immunotherapy for hematological malignancies. While engineered interleukin15 (IL15) variants like membrane-bound IL15 (mbIL15) and the IL15/IL15Rα heterodimer (RLI) can enhance NK cell activity, their relative eff… |
Clinical Result source | ClinicalTrials.gov NCT05020015 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT05020015 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | KN5501 (anti-CD19 CAR NK cells, anti-CD19 CAR NK cells (KN5501)) Rui Therapeutics Co., Ltd·CD19 33 trials |
|---|---|
Overview Program | anti-CD19 CAR NK cells (KN5501) |
Overview Company | Rui Therapeutics Co., Ltd |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Systemic Lupus Erythematosus (SLE) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Constitutive RLI Armoring Enhances CAR-NK Cell Effector Functions but Causes Lethal Toxicity In Vivo.. Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is a promising immunotherapy for hematological malignancies. While engineered interleukin15 (IL15) variants like membrane-bound IL15 (mbIL15) and the IL15/IL15Rα heterodimer (RLI) can enhance NK cell activity, their relative eff… |
Toxicology CRS | Reported |
Clinical Safety signal | Constitutive RLI Armoring Enhances CAR-NK Cell Effector Functions but Causes Lethal Toxicity In Vivo.. Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is a promising immunotherapy for hematological malignancies. While engineered interleukin15 (IL15) variants like membrane-bound IL15 (mbIL15) and the IL15/IL15Rα heterodimer (RLI) can enhance NK cell activity, their relative eff… |
Clinical Result source | ClinicalTrials.gov NCT05020015 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT05020015 |
추천 비교
추천 비교